Sarepta Therapeutics shares dip despite ongoing legal challenges

Sarepta Therapeutics shares are trading lower after Piper Sandler downgraded its price target from $36 to $32 and Leerink Partners cut their target from $50 to $45, amidst ongoing securities class action lawsuits related to the ELEVIDYS treatment.